Market Overview

UPDATE: Stifel Reiterates on Aerie Pharmaceuticals as Timelines Are on Track

Related AERI
Aerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale A Record
Mid-Afternoon Market Update: Hudson Technologies Drops Amid Concerning Guidance; Aerie Pharmaceutical Shares Gain

In a report published Wednesday, Stifel analyst Annabel Samimy reiterated a Buy rating on Aerie Pharmaceuticals (NASDAQ: AERI), and raised the price target from to $22.00 to $24.00.

In the report, Stifel noted, “AERI reported 4Q13 revenue loss of $10.3mn translating to $0.62 loss-per-share with initial AR-13324/Rhopressa launch expected by 2017. Importantly, PG324/Roclatan's Phase 2b trial results are expected by early 3Q14. Additionally, AERI plans to initiate their Phase 3 for Rhopressa in 3Q14 (results mid-2015). Given recent episcleral venous pressure findings, Rhopressa's role in lowering pressure in normotensive patients (IOPs #26 mmHg, representing ~80% of patients, and IOPs #21 mmHg representing ~60%), AERI can now better position Rhopressa as front-line agent, with added cosmetic advantages over PGAs.

"As of February 28th, AERI has $67.6mn in cash, expected to last through Rhopressa's NDA filing and Roclatan's Phase 3 preparation. Overall, AERI continues to perform ahead of expectations and we raise our TP to $24 on stronger Rhopressa positioning.”

Aerie Pharmaceuticals closed on Tuesday at $21.89.

Latest Ratings for AERI

Oct 2017GuggenheimInitiates Coverage OnBuy
Oct 2017Canaccord GenuityMaintainsBuy
Sep 2017MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for AERI
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Price Target Analyst Ratings


Related Articles (AERI)

View Comments and Join the Discussion!

Partner Center